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ABSTRACT
Casein kinase 1 (CK1) plays central roles in various signal
transduction pathways and performs many cellular activities. For
many years CK1 was thought to act independently of modulatory
subunits and in a constitutive manner. Recently, DEAD box RNA
helicases, in particular DEAD box RNA helicase 3 X-linked (DDX3X),
were found to stimulate CK1 activity in vitro. In order to observe CK1
activity in living cells and to study its interaction with DDX3X, we
developed a CK1-specific FRET biosensor. This tool revealed that
DDX3X is indeed required for full CK1 activity in living cells. Two
counteracting mechanisms control the activity of these enzymes.
Phosphorylation by CK1 impairs the ATPase activity of DDX3X and
RNA destabilizes the DDX3X–CK1 complex. We identified possible
sites of interaction between DDX3X and CK1. While mutations
identified in the DDX3X genes of human medulloblastoma patients
can enhance CK1 activity in living cells, the mechanism of CK1
activation by DDX3X points to a possible therapeutic approach in
CK1-related diseases such as those caused by tumors driven by
aberrant Wnt/β-catenin and Sonic hedgehog (SHH) activation.
Indeed, CK1 peptides can reduce CK1 activity.
KEY WORDS: CK1 biosensor, Protein Ser/Thr kinase, RNA helicase
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INTRODUCTION
CK1 kinases are serine/threonine (Ser/Thr) protein kinases that were
considered to act as monomers and independently of cofactors.
Members of the CK1 family are involved inmany different biological
processes through phosphorylation of myriad substrate targets,
including key components of signaling cascades with well-
established roles in development, tumor initiation and tumor
progression (Knippschild et al., 2014). The involvement and
requirement of CK1 family members in Wnt/β-catenin signaling
has been studied extensively (reviewed in Clevers and Nusse, 2012;
Knippschild et al., 2005; Niehrs and Acebron, 2012). Moreover, an
increasing number of reports link altered CK1 expression or activity
to cancer (Knippschild et al., 2005; Dolezal et al., 2010; Fuja et al.,
2004; Lin et al., 2014;Modak andChai, 2009; Rodriguez et al., 2012;
Schittek and Sinnberg, 2014), indicating that regulation and control
of CK1 activity is of high importance for cells. Although CK1
isoforms were long considered to be constitutively active kinases
(Tuazon and Traugh, 1991), subcellular localization and post-
translational modifications (especially phosphorylation) of CK1
isoforms may contribute to the regulation of their kinase activity.
Another molecular control mechanism was recently suggested by the
finding that DEAD box RNA helicases, in particular DDX3X, are
able to modulate CK1 kinase activity in vitro by enhancing the
velocity of the kinase reaction (Cruciat et al., 2013).
Several reports linked mutations in DDX3X to tumors that are
caused by uncontrolled Wnt/β-catenin or SHH signaling pathways
(Jones et al., 2012; Kool et al., 2014; Pugh et al., 2012; Robinson
et al., 2012). As CK1 activity plays important roles in these two
signaling pathways, we started to investigate the cellular role of
DDX3X in activating CK1 in living cells and the mechanisms by
which the carcinogenic mutations in DDX3X could affect these two
signaling pathways. Towards this end, we developed a biosensor
that is capable of specifically monitoring CK1 activity in the cell
over time. The results showed that the DDX3X–CK1 interaction is
essential for high levels of CK1 activity in living cells. We further
present results that indicate that the CK1-activating function of the
RNA helicase DDX3X is regulated by phosphorylation and by
RNA binding. These studies demonstrate the importance of the role
of DDX3X in activating CK1 in living cells and suggest that this
enhancement is not properly controlled in mutant DDX3X that is
associated with medulloblastoma.
RESULTS
A CK1 biosensor specifically monitors CK1 activity in living
cells
In order to analyze CK1 activity directly in living cells and to explore
the effects of possible co-factors on CK1 activity, we generated a CK1
biosensor on the basis of a ratiometric FRET (Förster resonance
energy transfer) sensor (Fritz et al., 2013; Hukasova et al., 2012;
Komatsu et al., 2011). The CK1 FRET biosensor was constructed
by substituting the sensor domain of AKAR3EV, a protein kinase
A (PKA) sensor (Komatsu et al., 2011) with the non-canonical
CK1 recognition sequence RRKDLHDDEEDEAMTIAD and with
RRKDLHDDEEDEAMAIAD for the non-phosphorylatable T/A
control (Fig. 1A). The unimolecular sensor consists of two
fluorophores (eCFP and YPet) separated by three different domains:
the phosphorylation motif domain, containing a non-canonical
phosphorylation motif for CK1 (D/En-X-X-T), where T517 is
targeted for phosphorylation, the phospho-binding domain FHA1
(forkhead-associated domain 1; Durocher and Jackson, 2002) and aReceived 12 June 2017; Accepted 13 November 2017
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linker domain that separates the two neighboring domains (Fig. 1A).
The phosphorylation motif domain is also called the CK1 sensor
domain (CK1 SD). In its phosphorylated state (pT517), CK1SD binds
to the ligand domain FHA1 and induces a conformational change that
reduces the distance between the two fluorophores YPet and eCFP as
well as their orientation towards one another, leading to an increase in
Fig. 1. The CK1 biosensor specifically responds to CK1 activity. (A,B) Domains of FRET-based CK1 biosensor (A) and its schematic activity (B). YPet, yellow
fluorescent protein variant; FHA1, Forkhead-associated domain 1; EV-Linker, Eevee linker; CK1 SD, CK1 sensor domain; eCFP, enhanced cyan fluorescent
protein; NES, nuclear export signal. (C) Emission spectra in HEK293T cells transiently expressing CK1 sensor (black) or T/A control (gray). Excitation wavelength:
433 nm; au, arbitrary units. (D) FRET/CFP ratio is distinct for CK1 sensor and T/A control. (E) Phosphopeptide analysis of immunopurified CK1 sensor. The
phosphosites in the biosensor are shown in A. (F-H) CK1 sensor reacts to overexpression of CK1 and to the CK1-specific inhibitor D4476. HEK293T cells expressing
CK1 sensor or T/A control and, if indicated, CK1ε. CK1 inhibitor application (D4476) is also indicated. CK1 sensor and T/A control were normalized separately
and set to 1. +, 0.4 μMD4476; ++, 2 μMD4476. (G) Emission spectrameasured fromHEK293T cells transiently expressing the CK1 sensor alone (black), with CK1ε
(green) or in the presence of the CK1 inhibitor D4476 (red, 2μM). Excitation wavelength: 433 nm; a.u. arbitrary units. (H) Dose dependence of CK1 inhibition by
D4476monitored in HEK293T cells transiently transfected with CK1 sensor construct. (I) Other CK1 inhibitors also affect the CK1 sensor. HEK293T cells expressing
CK1 sensor treated with different compounds (CPD). Error bars indicate s.d., n=3. Asterisk reflects Student’s t-test: *P<0.05, ***P<0.001.
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FRET (Fig. 1B). The FRET/CFP ratio of the emission signal serves as
a readout for the T517 phosphorylation levels as already described for
biosensors for other kinases (Komatsu et al., 2011). A nuclear export
signal (NES) directs this biosensor into the cytoplasm for monitoring
of cytoplasmic T517 phosphorylation and CK1 activity.
Quantifications of the FRET/CFP ratio were performed in a
microplate reader. eCFP was excited and the emission spectra of
cells expressing the biosensor were measured. They displayed
two peaks for the two individual fluorophores (Fig. 1C).
Phosphorylation-independent FRET changes were monitored by
using a mutated sensor in which the essential CK1 target site was
changed from Thr to Ala (T517A, named T/A control). This led to
an overall reduced FRET/CFP ratio (Fig. 1C,D). LC-MS/MS
analysis of the purified sensor from either control cells or from
HEK293T cells overexpressing CK1ε confirmed the expected
phosphorylation changes at T517, whereas a phosphorylation site
outside the CK1 target sequence, S269, was unaffected (Fig. 1E).
Importantly, the FRET/CFP ratio of the T/A control sensor was not
significantly altered by the same experimental conditions (Fig. 1F),
thus indicating that the observed changes are phosphorylation
dependent. Note that the FRET/CFP ratio is shown relative to the
ratio measured when cells overexpress the respective sensor only
(either CK1 sensor or T/A control sensor). Next, we demonstrated
the ability of the sensor to respond to cellular CK1 activity in the
presence of the small-molecule CK1 inhibitor D4476 and other
published CK1 inhibitor compounds [CPD17 (Peifer et al., 2009);
CPD5 (Bischof et al., 2012); and CPD2 (Richter et al., 2014)]. The
FRET/CFP ratio was reduced as a result of the inhibitor treatment
whereas it was elevated when CK1ε was overexpressed (Fig. 1F–I).
The general CK1 phosphorylationmotif used in the sensor allowed
us to detect the enhanced CK1 activation driven by overexpression of
different CK1 isoforms. All isoforms enhanced the FRET/CFP ratio
of the CK1 sensor, but the ratio of FRET/CFP was highest upon
overexpression of CK1α1, despite all CK1 isoforms being expressed
at roughly comparable levels (Fig. 2A). Indeed, CK1α1 has a slightly
lower expression level, which indicates that its effect on the sensor is
underestimated. Stimulation of the sensor by overexpression of
different CK1 isoforms could also be observed microscopically in
individual cells (Fig. 2B,C). This analysis clearly shows that the
sensor measures CK1 activity in living cells. Co-expression of the
kinase-dead mutant of CK1ε (CK1εK38R; Fig. 2D) did not enhance
the FRET/CFP ratio of the sensor. This proved that the structural
protein of CK1ε is not sufficient to induce a change in the FRET/CFP
ratio of the sensor, which is also consistent with the notion that the
FRET/CFP ratio monitors the CK1 kinase activity.
Next, we tested the specificity of the sensor for this particular kinase
subgroup. Various other cytoplasmic protein kinases did not affect the
FRET/CFP ratio, namely CDK2 (cyclin-dependent kinase 2), CK2α
(casein kinase 2 α-subunit), NLK1 (nemo-like kinase, type 1) and
GSK3β (glycogen synthase kinase 3β), as well as ERK1, ERK2
(extracellular-regulated kinases 1 and 2) and constitutively active RAF
(rapidly accelerated fibrosarcoma; Fig. 2D,E). As an additional control,
the protein kinase A (PKA) sensor, which provided the framework
for the CK1 sensor, was analyzed alongside the CK1 sensor. Co-
expression of CK1 isoforms led to a specific increase of the FRET/
CFP ratio from the CK1 sensor, but not from the original PKA sensor,
thus corroborating the specificity of the CK1 sensor (Fig. 2F).
DDX3X is required for full cellular CK1 activity and
synergizes specifically with CK1ε
Previous in vitro experiments had suggested that DDX3X influences
the activity of CK1 by direct protein–protein interaction (Cruciat
et al., 2013). Analyzing the CK1 biosensor in siDDX3X-treated cells
revealed that the FRET/CFP ratio was reduced to approximately the
same level as that in cells treated with the CK1 inhibitor D4476,
demonstrating that DDX3X is required for normal activity of CK1 in
living human cells (Fig. 3A, Fig. S1A,B). Previously, it was shown
that DDX3X synergizes with CK1ε to induce Dishevelled (Dvl)
phosphorylation and thereby activates Wnt/β-catenin signaling
(Fig. S1C; Cruciat et al., 2013). This synergy was corroborated
with the microplate assay as well as with single cell measurements.
Expressing CK1ε together with DDX3X led to a significantly
enhanced FRET/CFP ratio, indicative of enhanced CK1 kinase
activity (Fig. 3B–D). Moreover, DDX3X expression alone was not
sufficient to significantly enhance endogenous CK1 activity, which is
consistent with previous results showing that DDX3X is required, but
not sufficient for Wnt signaling and Dvl hyperphosphorylation
(Cruciat et al., 2013). Under co-expression conditions, DDX3X
predominantly synergized with limiting amounts of CK1ε rather than
with CK1δ and CK1α isoforms (Fig. 3E). This might point to CK1ε
being the predominant DDX3X-stimulated CK1 isoform in
HEK293T cells. In summary, using the specific FRET-based CK1
biosensor we were able to show that DDX3X is required for full CK1
activity in living cells.
ATPase and kinase-activating functions of DDX3X appear to
be mutually exclusive
We next investigated the connection between the two biological
activities of DDX3X: its enzymatic RNA helicase function and its
kinase-activating function. In general, the addition of RNA to
DEAD box RNA helicases stimulates their ATPase activity (Linder
and Jankowsky, 2011). Interestingly, however, if CK1ε was added,
the RNA-stimulated ATPase activity of full-length DDX3X purified
from HEK293T cells was reduced to background levels (Fig. 4A).
As an additional control to ascertain whether the RNA helicase
activity indeed derives from DDX3X and not from other helicases,
we extensively washed the purified DDX3X and checked the
recombinant proteins for co-purification of other RNA helicases
known to bind to DDX3X, such as DDX5 and RIG-1 (also known
as DDX58). These RNA helicases were not detectable in the
purified DDX3X fraction, suggesting that DDX3X did not form
unspecific large RNA helicase aggregates and that our assay indeed
analyzed the helicase activity of DDX3X (Fig. S1D).
The observed inhibition of the ATPase activity of DDX3X might
be caused either by phosphorylation of DDX3X or by a structural
change induced by the binding of CK1ε. Two previous studies have
already shown that DDX3X becomes phosphorylated by kinases
while stimulating their activity (Cruciat et al., 2013; Gu et al., 2013).
In order to identify DDX3X residues that can be phosphorylated by
CK1ε, mass spectrometric analyses were performed using the
DDX3X helicase core (aa 168–582) and the C-terminal helicase
domain (aa 414–582). Although phosphorylation of S429 and S543
could be identified for the DDX3X helicase core, residues T469,
S470 and S543 were found to be in a phosphorylated state in the
C-terminal helicase domain (Table 1). As can be seen in Fig. 4B,
pre-incubating CK1ε with the CK1 inhibitor D4476 prevented
inhibition of the ATPase activity of DDX3X, indicating that CK1ε
kinase activity is needed for this inhibitory effect. To further test this
hypothesis, DDX3X was pre-incubated with the constitutively
active CK1εΔC (CK1ε lacking its regulatory C-terminal domain) to
allow phosphorylation of DDX3X in vitro (Fig. 4B, last four lanes).
The helicase activity of this phosphorylated DDX3X was much less
stimulated by dsRNA. Pre-treating DDX3X with the kinase-dead
mutant CK1εΔCK38R as a control still allowed dsRNA stimulation
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of the ATPase activity (‘non-P-DDX3X’ in Fig. 4C,C′). Overall, the
general ATPase activity was diminished after this treatment.
However, when comparing the relative levels, DDX3X pre-
incubated with the active form of the kinase showed reduced
ATPase activity, implying that phosphorylation of DDX3X impairs
its ATPase activity.
Next, we tested whether the enzymatic activity of the helicase
influences the kinase-activating function of DDX3X. For this, we
added RNA to the in vitro kinase assay. Double-stranded RNA
(dsRNA) or single-stranded RNA (ssRNA) impaired the kinase-
activating potential of DDX3X without significantly affecting
CK1ε activity at the concentrations used (Fig. 4D, Fig. S1E,F).
Importantly, pre-incubation of DDX3X with RNA clearly reduced
its binding to CK1ε (Fig. 4E). This suggests that RNA interferes
with the formation or stability of the DDX3X–CK1ε complex.
Mapping and modeling the interaction between DDX3X and
CK1
We set out to identify the minimal domain of CK1 that is required
for interaction with DDX3X. Previous studies had already indicated
that the C-terminal helicase domain of DDX3X is sufficient to
enhance CK1 activity (Cruciat et al., 2013). We found that the
DDX3X region containing only residues 414–582 was sufficient for
the kinase stimulation function (Fig. S1G). In order to narrow down
the regions within the CK1 protein that interact with DDX3X, we
took advantage of a peptide library that was synthesized based on
the sequences of CK1δ and CK1ε (Fig. 5A, Fig. S2). Cruciat et al.
(2013) found that all CK1 isoforms, including CK1δ and CK1ε,
were activated by DDX3X in vitro. Because this activating effect
was most pronounced for C-terminally truncated CK1ε and because
CK1δ and CK1ε display very high sequence similarity, we focused
Fig. 2. CK1 isoforms stimulate the CK1
sensor and not other tested kinases. (A) All
tested CK1 isoforms are able to stimulate the
CK1 sensor. CK1 sensor only and T/A control
only were normalized separately and set to
1. Expression of CK1 isoforms in transfected
HEK293T cells analyzed by western blotting is
shown on the right. (B) Live imaging of cells
expressing CK1 sensor and different CK1
isoforms. Heatmap displays FRET/CFP ratio.
Scale bar: 10 µm. (C) Live imaging of cells
transfected with CK1 sensor and CK1
isoforms. Single cell analyses displaying
FRET/CFP ratios. (D,E) CK1 sensor is
stimulated by CK1 isoforms and not by other
cytoplasmic kinases. HEK293T cells
transiently transfected with CK1 sensor and
indicated constructs. c.a. RAF: constitutively
active RAF. (F) CK1 sensor reacts to higher
CK1 levels whereas PKA sensor does not.
Error bars indicate s.d., n=3. ***P<0.001,
Student’s t-test.
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on peptides derived from the kinase domain of CK1δ and CK1ε.
The interaction between different CK1 peptides and the minimal
CK1-activating fragment His-DDX3X414-582 was initially assessed
by ELISA. The strongest binding was observed for peptides δ-31,
ε-61, δ-91, δ-141 and ε-241, and to a lesser extent also for peptides
δ-1, δ-41, ε-41 and δ-231 (the number indicates the position of the
N-terminal amino acid of each 15mer peptide in the full-length
sequences of CK1δ or CK1ε; Fig. 5B; Fig. S3A,B). Peptide δ-341,
originating from the C-terminal domain of CK1δ, served as negative
control. Peptide δ-101 showed no binding and was therefore chosen
as an additional negative control for subsequent experiments.
In order to validate these initial data, the CK1δ-/CK1ε-derived
peptides that showed binding to His-DDX3X414-582 in the ELISA
assay were also tested in fluorescence thermal shift (FTS) assays to
determine whether they enhance the stability of His-DDX3X414-582.
This would also be indicative of binding. Indeed, in the presence of
peptides δ-1 and δ-41, the melting temperature (Tm) of His-
DDX3X414-582 increased by 3.5 and 5°C, respectively (Fig. 5C). For
the δ-1 and δ-41 peptides, dissociation constants (Kd) of 15.61 and
5.49 µM, respectively, could be determined for their interaction
with the DDX3X fragment (Fig. S3C), establishing these as putative
DDX3X binding sequences. Interestingly, the peptides ε-1 and ε-41
also caused significant Tm changes of His-DDX3X414-582 (4.6 and
6.3°C, respectively; Fig. 5C). These peptides originate from the
CK1ε amino acid sequence and show only minor sequence
differences to the corresponding CK1δ peptides δ-1 and δ-41
(Fig. S2). The negative control peptides δ-101 and δ-341 did not
cause Tm shifts (Fig. 5C).
If the interactions between the identified CK1 peptides and
DDX3X reflect the interactions that are relevant for the activation of
CK1 by DDX3X, these peptides may block access of DDX3X to the
CK1 protein and this should then lead to impaired kinase activation.
Indeed, in vitro incubation of CK1 peptides δ-1, δ-41 and ε-41 with
recombinant DDX3X impaired the stimulation of CK1ε kinase
activity without affecting kinase activity itself (Fig. 5D,E). In
contrast to these three peptides, ε-1 and the non-binding control
peptide δ-101 did not interfere with the DDX3X stimulation. To test
whether these peptides also affect endogenous CK1 activity in
living cells, we transfected the aforementioned peptides into cells
expressing the CK1 biosensor and measured the resulting FRET/
Fig. 3. DDX3X is required for full CK1
activity in human cells. (A) DDX3X is
required for CK1 activity. Transiently
transfected HEK293T cells expressing
the CK1 sensor and indicated constructs.
Small interfering RNAs (siDDX3X), a
mock target (siControl) and CK1 inhibitor
(D4476) were applied. (B) DDX3X
synergizes with CK1ε to enhance FRET/
CFP ratio of CK1 sensor. (C,D) Live
imaging of cells transfected with CK1
sensor and indicated constructs.
(C) Heatmap of transfected HEK293T
cells displaying FRET/CFP ratio in a color
look-up table. Scale bar: 10 µm. (D)
Single-cell analysis of FRET/CFP ratio in
living cells reveals cooperation of CK1ε
and DDX3X. (E) At lower CK1 expression
levels, DDX3X mainly cooperates with
CK1ε in living cells. Error bars indicate
s.d., n=3. *P<0.05, **P<0.01, ***P<0.001,
Student’s t-test.
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CFP ratio. As can be seen in Fig. 5F,G, the transfection of the three
peptides δ-1, δ-41 and ε-41, but not ε-1 or the negative control
peptide δ-341, reduced the FRET/CFP ratio, indicating that peptides
δ-1, δ-41 and ε-41 interfere with endogenous CK1 activity in living
cells.
Biolayer interferometer (BLItz) binding studies showed that the
C-terminal helicase domain of DDX3X strongly interacted with δ-1
rather than with δ-41 or the control peptide δ-101 (Fig. 5H). Within
the three-dimensional structure of CK1δ [Protein Data Bank (PDB)
accession no.: 4TWC; Bischof et al., 2012] peptides δ-1 and δ-41
are located in a well exposed position on the surface of the kinase’
N-lobe. These structures as well as their CK1ε counterparts
therefore seem in a good position to interact with DDX3X
(Fig. 5I). To better understand the interaction between the
peptides and DDX3X we modeled the binding of the δ-1 and
δ-41 peptides to DDX3X using the Schrödinger Suite ‘Maestro’ as
molecular modeling software. The results suggested that peptides
δ-1 and δ-41 bind inside the cleft between the N-terminal and
Fig. 4. CK1 counteracts ATPase activity of DDX3X by direct phosphorylation and RNA neutralizes the kinase stimulatory function of DDX3X. (A,B)
ATPase assay with recombinant proteins and dsRNA titration (+, 17 nMRNA; ++, 34 nMRNA). (A) RNA-induced ATPase activity of DDX3X is impaired by CK1ε.
(B) Phosphorylated DDX3X displays impaired ATPase activity. P-DDX3X, DDX3X pre-treated with CK1ε to allow phosphorylation. Note that because the
pretreatment of the helicase might affect the enzyme activity in additional ways, it is not clear whether the last 4 columns can be quantitatively compared with the
rest (indicated bya dashed line). The controls in C, however, show that at least a large fraction of the effect is due to the kinase activity of CK1ε. dsRNA titration: 17,
34, 68 nM, respectively. (C,C′) CK1ε-induced phosphorylation of DDX3X impairs ATPase activity of the RNA helicase in vitro. ATPase assay with recombinant
proteins. Recombinant DDX3X was pre-treated either with CK1ε to allow phosphorylation (P-DDX3X) or with the kinase-dead mutant CK1εK38R (non-P-DDX3X).
PhosphoImager blot is shown below. (D) RNA inhibits DDX3X-induced CK1 activation. Radioactive kinase assay with recombinant proteins and CK1 peptide
substrate. Where indicated, recombinant DDX3X was pre-treated with either dsRNA or ssRNA. (E) RNA impairs complex formation or stability of CK1ε and
DDX3X. Purified Flag-DDX3X protein was incubated with total RNA where indicated and subjected to bead-coupled HA-CK1ε. n.s., not significant. Error bars
indicate s.d., n=3.
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C-terminal domains of DDX3X (Fig. 5J; PDB: 2I4I; Högbom et al.,
2007). For peptide δ-341, which we have used as a negative control,
molecular modeling revealed that effective binding to DDX3X
would be sterically hindered (Fig. 5J). Based on this binding
simulation, the binding peptides δ-1 and δ-41 might interfere with
the access to the RNA- and ATP-binding motives of DDX3X. These
include the adenine-binding motif Q, the P-loop in motif I that
interacts with the phosphate moiety of ATP, and motif VI, which
possibly participates in ATP hydrolysis (Cordin et al., 2006;
Högbom et al., 2007).
DDX3X mutations associated with medulloblastoma
hyperstimulate CK1 activity
Exon sequencing of medulloblastoma patient samples revealed that
the occurrence of mutations within DDX3X is significant,
suggesting a causative connection (Jones et al., 2012; Kool et al.,
2014; Pugh et al., 2012; Robinson et al., 2012). Medulloblastoma
tumors are classified into four subgroups. Subgroups 1 and 2 are
associated with aberrant Wnt/β-catenin and sonic hedgehog (SHH)
signaling, respectively, and all identified DDX3X mutations
belonged to tumor samples of the Wnt or SHH subgroups (Kool
et al., 2014). Most mutations led to an amino acid change and were
distributed along the DDX3X helicase core domain (Kool et al.,
2014; Pugh et al., 2012). Pugh and co-workers demonstrated for
seven of these mutations that they synergistically hyperactivateWnt/
β-catenin signaling together with a mutated variant of β-catenin
(S33Y) that prevents its degradation (Pugh et al., 2012). The fact
that CK1 activity is needed in Wnt/β-catenin and SHH signaling
suggested that mutations in DDX3X might affect CK1 activity and
that this could be the reason why they cluster in the Wnt and SHH
medulloblastoma tumor groups. We therefore used the CK1
biosensor to test the hypothesis that mutant DDX3X versions
identified by Pugh et al. affect CK1 activity. Transfected into
HEK293T cells together with the sensor construct, the two DDX3X
mutantsDDX3XR376C andDDX3XR528H, which are located in the N-
terminal and C-terminal helicase domain, respectively, enhanced
the FRET/CFP ratio of the CK1 sensor significantly more strongly
than wild-type DDX3X did (Fig. 6A,B), even though wild-type
DDX3Xwas expressed at least as strongly as the mutants (Fig. S4A).
Enhancement of CK1 kinase activity by these mutant DDX3X
forms could be confirmed by studying their effect on the
phosphorylation of Dvl, a CK1 target in the Wnt pathway.
Analyzing Dvl phosphorylation levels by a shift detectable on
Western blots revealed that the mutant forms of DDX3X stimulated
Dvl phosphorylation whereas the wild-type protein alone could not
(Fig. 6C). This indicates that both mutants enhance CK1 activity in
living cells. In vitro kinase assays confirmed these results, as both
mutants were able to significantly enhance CK1ε activity (Fig. 6D).
At high dsRNA concentrations, DDX3XR376C and DDX3XR528H
proteins displayed reduced and no significant ATPase activity,
respectively, as shown previously for other DDX3X mutations
associated with medulloblastoma (Fig. 6E; Epling et al., 2015). We
considered the possibility that failure of the mutant DDX3X protein
to bind RNA might cause the CK1 hyperactivation phenotype.
However, in vitro RNA binding was still observed with the mutant
forms (Fig. S4B). By contrast, DDX3XR376C seemed to bind more
strongly to CK1ε than any of the other DDX3X variants (Fig. S4C),
suggesting that this mutation might enhance the binding affinity to
CK1ε. However, in co-localization experiments both mutant forms
of DDX3X showed the same distribution and co-localization pattern
as wild-type DDX3X with CK1ε (Fig. S4D).
Although complex formation between the wild-type helicase and
CK1 as well as subsequent activation of CK1 is generally impaired
upon addition of RNA (see Fig. 4E), mutant DDX3XR528H is still
able to stimulate and bind to CK1ε even in the presence of RNA
(Fig. 6F,G). DDX3XR376C, by contrast, behaves in this regard more
like the wild-type protein because dsRNA still inhibits its CK1
activation potential and binding to CK1 (Fig. 6F,G).
The CK1 sensor revealed that wild-type DDX3X mainly
cooperated with CK1ε in living cells and not with CK1α (Fig. 2A).
Interestingly, in cultured cells, both DDX3X mutations significantly
cooperated not only with CK1ε, but also with CK1δ and even more
strongly with CK1α (Fig. 6H). The finding that mutations inDDX3X
cause the activation of other CK1 isoforms besides CK1ε in living
cells is striking and might contribute to the pathological effects of
DDX3X mutations found in medulloblastoma.
DISCUSSION
In this study we developed a unimolecular biosensor enabling us to
monitor CK1 kinase activity in living cells. The sensor is specifically
phosphorylated by CK1 and the treatment of cells with CK1
inhibitors or overexpression of specific constructs caused the
expected changes in the FRET activity of the sensor. Thus, we
established a specific and sensitive biosensor that can be used to study
CK1 kinase regulation in signaling pathways. Employing this sensor
we demonstrated thatDDX3X is required for full activation of CK1 in
living cells. Specifically, knockdown of DDX3X reduces CK1
activity to the same level as that obtained by the addition of CK1
inhibitors, indicating that most or all of the cellular CK1 activity
towards the sensor depends on DDX3X. This is a surprising finding
given that for decades CK1 family members were regarded as
constitutively active enzymes. This earlier view was based on the fact
that all CK1 isoforms, once purified from cells, displayed kinase
activity (Tuazon and Traugh, 1991). However, the existence of a
CK1ε activation/inactivation cycle has already been demonstrated in
the signal transduction processes following activation of group I
metabotropic glutamate receptors. Within this cycle, CK1ε is
activated by calcineurin-mediated dephosphorylation and again
inactivated by intramolecular autophosphorylation (Liu et al.,
2002). Similarly, activation of CK1ε in Wnt signaling is mediated
via dephosphorylation of CK1ε by the PP2A catalytic subunit P61ε,
which is located at the Frizzled–LRP5/6 receptor complex (Vinyoles
et al., 2017). Especially in the context of Wnt signaling, both
dephosphorylation of CK1ε and interaction of CK1ε with DDX3X,
may cooperate to fully activate CK1ε. Focusing on the latter
mechanism, our results led to a detailed characterization of the
DDX3X-mediated activation of CK1ε, advancing the knowledge on
CK1 activity and regulation.
Although Cruciat and colleagues (Cruciat et al., 2013) previously
showed that DDX3X is able to stimulate CK1 isoforms α, δ and ε to
the same extent in vitro, our biosensor data showed that in living
cells only the activities of CK1δ and ε, but not CK1α, are stimulated
by co-expressed DDX3X. This finding might indicate that other
Table 1. DDX3X is phosphorylated by CK1ε in vitro
Probability of phosphorylation (%)*
S429 T469 S470 S543
His-DDX3X168-582 100 – – 88.7
His-DDX3X414-582 – 100 100 92.7
*Phosphorylated serine or threonine residues were detected by mass
spectrometry analysis following tryptic digestion during sample preparation
routine. His, 6× histidine tag; S, serine; T, threonine; –, no phosphorylation
detected.
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interaction partners of DDX3X exist within the cell. By acting as
scaffolding proteins these partners might recruit DDX3X
specifically to CK1ε and its highly related isoform CK1δ via their
C-terminal tails outside the kinase domain, but they would not
stimulate the interaction with the shorter isoform CK1α. This work
also provides new mechanistic insights into how the RNA helicase
Fig. 5. Fine-mapping of the CK1 interaction domain with DDX3X. (A) CK1δ- and ε-derived peptides were used to fine-map CK1 domains interacting with
DDX3X. Schematic representation of the CK1 peptide library illustrating the peptide differences of CK1δ versus CK1ε. (B) Binding of peptides to His-DDX3X414-
582 analyzed using ELISA. Data were normalized to peptide δ-141, which was set to 100%. (C) CK1δ-derived peptides can stabilize His-DDX3X414-582 in FTS
assays. (D,E) Peptides δ-1 and δ/ε-41 but not ε-1 and δ-101 inhibit DDX3X-stimulated CK1 activity in vitro. Radioactive kinase assay with indicated recombinant
proteins and peptides. CK1εΔC activity alone was set to 1 for each experiment. (F,G) Peptides δ-1 and δ/ε-41 reduce endogenous CK1 activity in cultured cells.
HEK293T cells transfected with CK1 sensor and indicated peptides were analyzed 1.5 h after peptide transfection. Peptide δ-341 served as negative control.
CFP/FRET ratio from cells only transfected with biosensor were set to 1 for each individual experiment. (H) Peptide δ-1 binds to the C-terminal DDX3X helicase
domain, and peptide δ-41 also displays a slight binding activity. BLItz analysis of biotin peptides with the C-terminal helicase domain of DDX3X. (I) Crystal
structure of CK1δwith indicated peptides δ-1 (P1, red) and δ-41 (P2, purple). (J) Molecular modeling suggests that peptides δ-1 and δ-41 (red) bind inside the cleft
between N-terminal domain (blue) and C-terminal domain (yellow) of DDX3X. For control peptide, δ-341 binding is sterically hindered and only lipophilic
interactions could be observed. Error bars indicate s.d., n=3.
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Fig. 6. Mutant DDX3X associated with medulloblastoma display enhanced CK1 activation. (A) Expression of CK1 sensor and mutated DDX3X enhances
CK1 activity. Microplate reader analysis of CK1 sensor and indicated constructs. (B) Schematic representation of DDX3X domains with strongest enhancing
point mutations. Dark gray, N-terminal helicase domain; light gray, C-terminal helicase domain. (C) DDX3XR376C and DDX3XR528H stimulate Dvl phosphorylation.
Western blot of lysate from transfected HEK293T cells; +, 50 ng transfected Flag-DDX3X DNA; ++, 100 ng transfected Flag-DDX3X DNA. (D) DDX3X
mutant proteins display enhanced CK1 activation potential in vitro. Radioactive kinase assay with CK1 peptide substrate and recombinant DDX3X proteins.
(E) DDX3Xmutant proteins show impaired ATPase activity. ATPase assay with recombinant Flag-DDX3Xmutant proteins. ATPase activity was stimulated by two
different doses of double-stranded RNA (+, 17 nM dsRNA; ++, 34 nM dsRNA). (F,G) RNA interferes with CK1 activation and binding to DDX3X WT and
mutant R376C. This is much less pronounced with mutant R528H. (F) Radioactive kinase assay with CK1 peptide substrate and recombinant DDX3X proteins.
Each condition with DDX3X or kinase alone was set to 1. RNA was added where indicated. (G) Western blot with purified Flag-DDX3X proteins. These were
incubated with total RNA where indicated and subjected to bead-coupled HA-CK1ε. (H) DDX3X mutant proteins synergize with all tested CK1 isoforms.
Microplate reader analysis of CK1 sensor and indicated constructs. FRET/CFP signal was set to 1 for each CK1 isoform expressed alone. Error bars indicate s.d.
n=3. *P<0.05, **P<0.01, Student’s t-test.
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DDX3X performs its multiple functions in the cell (Fig. S4E). First,
RNA-bound DDX3X displays ATPase activity and fails to stimulate
CK1ε kinase, presumably as a result of reduced binding between the
two proteins. The modeling (Fig. 5I,J) suggests that CK1 interacts
with the open conformation of DDX3X, and RNA binding could
therefore interfere with the CK1–DDX3X interaction by inducing
the closed form of DDX3X and/or bymasking the CK1 binding site.
Second, CK1 counteracts the ATPase activity of the RNA helicase
DDX3X by direct phosphorylation. This mechanism explains, how
the moonlighting RNA helicase DDX3X is able to perform different
and apparently alternative biological activities. Its helicase function
does not seem to be required for its kinase-activating function and it
is even reduced by phosphorylation when it interacts with the
kinase. Indeed, only a rather small structural part of DDX3X is
required for the kinase activation function as the C-terminal helicase
part alone, which does not possess helicase activity, is sufficient to
stimulate the kinase. Interestingly, a kinase-activating function of
DDX3X has been suggested for another kinase, too. Gu and
colleagues showed that DDX3X directly interacts with the kinase
IKKε (IKBKE) to promote its autophosphorylation and activation
(Cruciat et al., 2013; Gu et al., 2013). However, it remains to be
determined whether the underlying mechanisms are comparable to
the activation of CK1 isoforms.
CK1, in turn, is also able to phosphorylate DDX3X. However,
the exact targets of phosphorylation have not yet been determined.
By using mass spectrometry we determined several sites within
DDX3X that are phosphorylated by CK1ε. However, the functional
consequence of CK1ε-mediated site-specific phosphorylation
remains to be determined in future studies. Although general
phosphorylation of DDX3X by CK1 has been shown to reduce the
enzymatic activity of the RNA helicase (Fig. 4; Cruciat et al., 2013;
Gu et al., 2013), the modeling simulation suggests a second
mechanism that may contribute to the reduction of this enzymatic
activity. The CK1 peptides that interfere with the stimulation of
DDX3X were modeled to bind in the vicinity of the RNA and ATP-
binding sites of DDX3X, suggesting that the kinase may block these
sites upon interaction. The interaction with the kinase may therefore
interfere with binding of the helicase to the RNA, thereby ensuring
that DDX3X remains a kinase activator.
The fine-mapping of CK1δ and CK1ε domains that interact with
DDX3X was performed using a peptide library derived from CK1δ
and CK1ε, which demonstrated the power of peptides as biological
tools. Peptides δ-1 and δ-41 in particular, as well as their CK1ε
homologs ε-1 and ε-41, displayed strong binding to DDX3X in vitro.
In addition to ELISA, peptide–protein interactions were validated by
FTS and BLItz assays. However, no binding of peptide δ-41 could be
observed in BLItz assays. Our results therefore highlight the
advantage of the FTS assay, which can be used to measure a wide
range of affinities with no surface-fixed components. All components
are measured in aqueous solution as free phase. Finally, binding of
peptides δ-1, ε-1, δ-41 and ε-41 could be clearly demonstrated by
FTS assay and with the exception of peptide ε-41 all of these peptides
also showed remarkable effects in subsequent analyses.
Peptides δ-1, δ-41 and ε-41 reduced the interaction between
DDX3X and CK1ε in the binding assays, further supporting the
view that the sequences covered by these peptides might reflect
actual binding sites for DDX3X on CK1δ and CK1ε proteins
(Fig. 5B,C). In cell culture, these three peptides reduced the CK1
activity in our CK1 biosensor studies (Fig. 5F,G). While this
reduction was evident, it was less pronounced compared with that
observed with the CK1-specific small-molecule inhibitors or
siRNA directed against DDX3X. This difference could be due to
limited uptake of the peptides into the cells or degradation of
peptides within the cells. For a more efficient use of peptides as CK1
inhibitors for cultured cells, cell-penetrating peptide sequences or
nanoparticle-mediated peptide delivery could be used instead. We
also noted that even a conservative single amino acid change from R
to K had a strong effect in this assay. The CK1 peptides δ-1 (R) and
ε-1 (K) differ only in this position in the middle of the peptide
(Fig. S2) and peptide δ-1 was able to reduce the FRET/CFP ratio,
whereas ε-1 did not (Fig. 5F,G). Further studies are needed to find
out the basis of this different behavior.
The CK1 FRET biosensor monitors CK1 activity in living cells,
providing a tool to analyze the importance of in vivo stimulation of
CK1 byDDX3X and whether this activity needs to be regulated. This
allowed us to start studying humanmalignancies that involve changes
inDDX3X. Several reports had linkedmutations inDDX3X to tumors
that are caused by overactive Wnt/β-catenin or SHH signaling
pathways. Medulloblastoma, the most common form of brain cancer
in children, is one of these (Jones et al., 2012; Kool et al., 2014; Pugh
et al., 2012; Robinson et al., 2012). Analyzing DDX3X mutants
discovered by Pugh et al. (2012) revealed that both mutants enhanced
CK1 activity in vitro and in cell culture (Fig. 6). Furthermore, as
opposed to the wild-type DDX3X, both mutant forms synergized not
only with CK1ε, but alsowith other CK1 isoforms. The basis of their
altered interaction with CK1 and their hyperstimulation of CK1
activity might be a stronger or more stable physical interaction with
CK1 that is independent of simultaneous binding of RNA.
Surprisingly however, this enhanced interaction only became
apparent in two different experiments. Whereas DDX3XR376C
showed enhanced binding to CK1ε in comparison to the wild-type
protein (Fig. S4C), binding of DDX3XR528H to CK1 was more
resistant to regulation by dsRNA (Fig. 6F,G).
The findings presented here shed new light on DDX3X and
its functions beyond its helicase activity. In the context of
medulloblastoma formation and other tumors involving Wnt/β-
catenin and SHH signaling mechanisms, such elevated CK1 kinase
activity and the loss of its control can lead to hyperstimulation of
these signaling pathways, thereby supporting tumor formation. It will
be similarly interesting to find out whether DDX3X or a related
DEAD box RNA helicase contribute to these signaling mechanisms
during normal development. The results presented here therefore
warrant further investigations into the role of DEAD box RNA
helicases in the activation of the CK1 isoforms. The fluorescent CK1
sensor described in this study could prove useful to explore CK1
activity in living cells and even in tumor models used to study the
impact of CK1 activity on various signaling pathways. Furthermore,
our data also showed that not only CK1-specific small-molecule
inhibitors, but also peptides specifically blocking the interaction
between CK1 and DDX3X (or other reagents mimicking this effect)
could be considered as a therapeutic option for medulloblastoma or
other tumors sharing this mutational signature.
MATERIALS AND METHODS
Expression constructs
Human DDX3X (UniProt entry O00571) and its published mutants were
kindly provided by Thomas J. Pugh (Pugh et al., 2012) and human CK1ε
(UniProt entry P49674) by Christof Niehrs (Institute of Molecular Biology,
Mainz, Germany). The kinase dead mutant of CK1εK38R was ordered via
Addgene [deposited by David Virshup (Rivers et al., 1998)]. Kinases for
control experiments were a gift from Volker Heussler and Olivier Pertz
(ERK1, ERK2 and constitutively active RAF; Institute of Cell Biology,
Bern, Switzerland). CK2α, NLK1, CDK2 and GSK3β were from Herbert
Steinbeisser (formerly University of Heidelberg, Germany). CK1α was
cloned from HeLa cells. Tagged constructs were generated by inserting
10
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs207316. doi:10.1242/jcs.207316
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
full-length or deleted forms of the respective gene either into a pCS-based
vector containing a N-terminal Flag or HA tag for human cell culture work,
or into the bacterial expression vector pET28a (Novagen). The CK1εΔC
(wild type and mutant) deletion constructs lack the C-terminal 112 amino
acids. AKAR3EV (PKA FRET biosensor) was kindly provided by Prof.
Kazuhiro Aoki (Laboratory of Bioimaging and Cell Signaling, Graduate
School of Biostudies, Kyoto University, Japan). The CK1 FRET biosensor
was constructed by substituting the sensor domain of AKAR3EV, a protein
kinase A sensor (PKA sensor; Komatsu et al., 2011) with the non-canonical
CK1 recognition sequence RRKDLHDDEEDEAMTIAD and with
RRKDLHDDEEDEAMAIAD for the T/A control.
Cell culture and siRNAs
HEK293T and HeLa cells were maintained in Dulbecco’s modified Eagle’s
medium. Note that the cell culture mediumwas substituted by a Phenol Red-
free medium (FluoroBrite DMEM, Gibco) prior to microplate reader-based
fluorometric analysis. Metafectene (Biontex) or PEI (polyethylenimine,
Polysciences) were used for DNA transfections. siRNAs were purchased
from GE Healthcare Dharmacon and transfected either as a pool consisting
of all four siRNAs or single siRNAs using Dharmafect: siDDX3X-1: GC-
AAAUACUUGGUGUUAGA; siDDX3X-2: ACAUUGAGCUUACUCG-
UUA; siDDX3X-3:CUAUAUUCCUCCUCAUUUA; siDDX3X-4:
GGUAUUAGCACCAACGAGA.
Purification of recombinant DDX3X and CK1
Purification of Flag-DDX3X from HEK293T cells was performed as
described previously (Cruciat et al., 2013). Importantly, during the last
washes before elution, the beads were washed with a high-salt buffer
(150 mM NaCl) to prevent co-purification of endogenous CK1 protein.
Oligomerization control experiments with DDX3X168-582 revealed that only
very low levels of endogenous DDX3X were co-purified by oligomerizing
with Flag-DDX3X. For bacterial expression, the pET28a expression vectors
were transformed into Rosetta2 cells (DDX3X variants, Novagen) or
Lemo21(DE3) (CK1εΔC, NEB). Gene expression was induced by the
addition of 0.5 mM IPTG at OD600=0.5 and incubation continued for 16 h at
20°C. Cells were lysed by sonication in a lysis buffer consisting of 50 mM
Tris-HCl, 200 mM NaCl, 5 mM imidazole, 1 mM TECEP, pH 8.0. The cell
lysate was cleared by high-speed centrifugation and subjected to TALON
affinity chromatography resin (Clontech) according to the manufacturer’s
instructions. Proteins for ELISA and FTS were dialyzed in 50 mM HEPES,
pH 8 containing protease inhibitor (25 µg/ml aprotinin).
Biolayer interferometer experiments (BLItz)
Biolayer interferometry was measured on the BLItz system (Pall ForteBIO
LLC). High Precision Streptavidin biosensor chips were loaded three times
with 100 µM biotin-coupled CK1 peptides in 50 mM Tris-HCl (pH 7.5),
10 mMNaCl for 30 s, followed by a step to block free biotin binding sites with
10 µM biocytin. Association and dissociation times of DDX3X414-582
(250 µM) were fixed at 60 s. Binding and dissociation curves were recorded
three times.
Generation of CK1δ- and CK1ε-derived peptides
According to the amino acid sequences of the N-terminal and the kinase
domain of human CK1δ (UniProt entry P48730), 30 CK1δ-derived peptides
were generated. In order to investigate the effects of sequence-specific
differences in the sequence of CK1ε (UniProt entry P49674) compared with
CK1δ, seven additional CK1ε-derived peptides were generated (Fig. S2).
Each peptide consists of 15 amino acids with the first and last five amino
acids always overlapping the previous and the following peptide,
respectively. At the N-terminus the peptides were coupled to biotin via a
four amino acid spacer sequence (SGSG). For peptide position and sequence
information see Fig. S2. All peptides were pre-dissolved in DMSO (final
concentration of 12.5% DMSO in the peptide stock).
Direct-binding ELISA
His-DDX3X414-582 protein fragment was coated onto 96-well Nunc
MaxiSorp plates (NUNC, Denmark) at a final concentration of 0.01 µg/µl
in 100 mM sodium carbonate buffer (pH 9.6) at 4°C overnight. Unspecific
binding sites were blocked with 5% FCS in PBS. Biotinylated CK1δ- and
CK1ε-derived peptides (1 µg/well) were added and incubated for 2.5 h at
room temperature. DMSO (0.35%) and water were used as negative
controls. Detection of the bound biotinylated peptides was performed by
incubation with HRP-streptavidin (1:8000 in 0.5% FCS in PBS). Finally,
plates were incubated with ABTS detection reagent [50 mM potassium
phosphate buffer, pH 5.7, 5% ABTS solution (1 mg/ml), 0.05% H2O2].
Absorption was measured at 405 nm after incubation for 40 min.
Fluorescence thermal shift (FTS) assay
FTS reactions were performed in a total volume of 20 µl in 50 mM HEPES
(pH 8) and contained 10 µM His-DDX3X414-582, a final concentration of
20 µM of each indicated CK1δ- or CK1ε-derived peptide, as well as
10×SYPRO-Orange (Invitrogen). DMSO (0.35%) and water were used as
controls. Measurements were performed in a LightCycler 480 device for
real-time PCR (Roche) according to the manufacturer’s instructions.
Respective protein melting temperatures were calculated using the
protein-melting evaluation software supplied by Roche.
Determination of peptide dissociation constants (Kd)
Dissociation constants were determined using the FTS assay described above
and varying concentrations of the CK1δ-derived peptides. Following
preliminary assays, the peptide concentration range was adjusted and
centered with higher density of data points around the previously estimated
Kd value. DMSO was used as control. Protein-melting temperatures were
calculated using the protein-melting evaluation software supplied by Roche
and first fitted to a model for single site ligand binding using Prism 6
(GraphPad) as described in Vivoli et al. (2014). Since cooperative binding
could not be excluded, data were also fitted to a model for simple cooperative
ligand binding. Fit of data to the different models was compared using extra
sum-of-squares F test and data of the preferred model was chosen.
RNA synthesis
The RNA substrate used in RNA binding and ATPase assays was generated
with pGEM3 and pGEMMO1/2 vectors as described (Méthot et al., 1994).
Transcriptions were carried out as recommended by the supplier (Ambion).
RNA was purified and annealed as described in order to obtain double-
stranded RNAwith a short sequence of annealed nucleotides and overhangs
on both sides (Li et al., 2010). For kinase assay, we used either single-
stranded RNA derived from the pGEM3 construct or the annealed double-
stranded RNA from both vectors.
Kinase assays
Kinase assays were carried out essentially as described (Cruciat et al., 2013).
For kinase assays, full-length DDX3X protein was expressed and purified
from HEK293T cells as described for the ATPase assay. Deletion constructs
were purified from E. coli. The eluted proteins were visualized using
Coomassie Blue and the intensity of the protein bands was measured using
ImageJ. The amounts used for kinase assays were estimated based on this
staining. Where indicated, dsRNA was premixed with proteins at room
temperature (RT) for 15 min before subjecting samples to radioactive kinase
assays. The CK1 substrate peptide RRKDLHDDEEDEAMSITA for the
kinase assay and samples was analyzed using p81 phosphocellulose
(Biomol) as described (Zhai et al., 1992). 0.3 µM CK1δ/ε-derived and
control peptides were used (Schacherl et al., 2015). For mass spectrometric
analyses DDX3X helicase core (His-DDX3X168-582) as well as the
C-terminal helicase domain (His-DDX3X414-582) were in vitro
phosphorylated by CK1ε. Also, reactions without addition of kinase were
performed and analyzed in order to correct for false-positive results. Mass
spectrometry data acquisition and analysis of trypsin-digested samples were
performed at the Core Unit Mass Spectrometry and Proteomics (Ulm
University) essentially as described in Meng et al. (2016).
ATPase assays
For the ATPase assay, Flag-tagged DDX3X full-length constructs were
expressed in HEK293T cells. After purifying and eluting DDX3X from the
beads, an aliquot of the eluates was resolved by SDS-PAGE in order to
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monitor the different DDX3X levels via western blotting and ImageJ. Based
on this comparison, similar amounts of full-length DDX3X protein were
used. Approximately 100 ng Flag-DDX3X protein and 10 ng His-CK1ε
were used in a 60 μl reaction mix (reaction buffer: 20 mM Tris-HCl, pH 7.4,
200 mM NaCl, 0.5 mM DTT, 1 mM MgCl2, 1 mM ATP) with dsRNA
(17 nM, 34 nM, 68 nM); the reaction was carried out at 37°C for 40 min. To
phosphorylate DDX3X, 500 ng His-CK1εΔC or His-CK1εΔCK38R were
added in kinase buffer before eluting the DDX3X protein from the
Sepharose magnetic Flag beads (Sigma). Incubation was performed at 37°C
for 30 min. Then, beads were washed with 50 mM Tris-HCl, pH 7.5 and
500 mMNaCl before elution with Flag peptide. Termination of the helicase
reaction was done with 10 μl of 50% TCA solution added to each reaction
followed by centrifugation at 3000 g for 5 min at 4°C. Reaction mix was
mixed with coloring solution (35 mM ammonium molybdate, 10 mM zinc
acetate, 10% ascorbic acid, pH 5) in a 96-well plate before analysis using a
spectrometer (wavelength 700 nm).
Microplate reader-based fluorometric analysis
HEK293T cells were seeded at a density of 20,000 cells/well on 96-well
black microplates (PS, μClear, clear bottom, chimney well, Greiner No.
655090). Transfection was performed as described above. Unless
indicated otherwise, the respective cell populations were transfected
with 50-100 ng CK1 FRET biosensor, 100 ng regulator (i.e. N-Flag
DDX3X) and 1-10 ng kinase (i.e. N-Flag CK1ε). Either empty pCS2
N-Flag vector or luciferase were used to transfect the same amount of DNA
in every well. Generally, the different samples were run in triplicate for
each individual experiment. Owing to the varying values for the FRET/
CFP ratios based on transfection efficiency, cell density and the time point
of analysis, we always set the FRET/CFP ratio of cells only transfected
with the CK1 sensor to 1 in order to compare individual experiments.
Importantly, the individual figures with the CK1 sensor represent only
experiments performed on the same 96-well plate with the same cell
density, transfection efficiency and time point.
Where applicable, the small-molecule CK1 inhibitor D4476 (BioVision)
was added to the cells 2-4 h prior to the analysis. For each triplicate the
respective volume of D4476 (in DMSO) was added together with 1 μl
Fugene HD (Promega) to 60 μl serum-free medium. The solution was
mixed, incubated for 15 min and added to the cells. The addition of Fugene
HD is necessary because of the poor cell permeability of D4476 (Rena et al.,
2004). End concentrations of D4476 before transfection are indicated in
figure panels and do not necessarily reflect the uptake by the cells. In the
corresponding controls an equal amount of DMSO instead of the inhibitor
was added to the medium. Analysis was performed 48-60 h after
transfection on an Infinite M1000 PRO microplate reader (Tecan) by
exciting CFP with a wavelength of 433 nm and measuring the resulting
emission at 460-600 nm in 2 nm increments. Fluorometric spectra were
background subtracted with spectra recorded from wells with non-
transfected cells. Resulting FRET/CFP ratios were calculated by dividing
the intensity values at the respective peaks (478 nm for CFP, 528 nm for
YFP) and analyzed essentially as described (Fritz et al., 2013). Where
indicated, CK1δ/ε-derived peptides were transfected into cells using
Metafectene (Biontex) 1 hour before measurements.
Live-cell ratiometric FRET imaging
Cells were seeded at a density of 50,000 cells/compartment onCELLview cell
culture dishes with glass-bottom and four compartments (Greiner) 1 day
before transfection. Alternatively, 35 mm glass-bottom Petri dishes (Mat Tek,
P35G-1.5-10-C) were used. Dishes had been coated previously with 1% PEI
in PBS (10 min) or poly-L-lysine (30 min) to facilitate cell adherence.
Transfection was performed as described above using 100 ng CK1 FRET
biosensor, 200 ng N-Flag DDX3X and 10 ng N-Flag CK1ε for the respective
compartments. Cells were imaged 48 h later on a Leica TCS SP8 confocal
microscope (63× objective, 457 nm Argon laser line) with a heating chamber
set to 37°C. Ratiometric analysis was performed in ImageJ by calculating the
FRET/CFP ratio for each pixel and quantifying the mean ratios within the
cytoplasm of selected cells. Since the use of hybrid detectors (HyD) resulted
in negligible background fluorescence, no background subtraction was
performed during image analysis.
Immunoprecipitation of CK1 sensor and phosphopeptide
analysis
1000 ng CK1 FRET biosensor, 750 ng Flag-DDX3X and 100 ng CK1ε
were transfected into HEK293T cells seeded on 6-well plates. Extracts were
added to 50 μl magnetic beads (XS Protein G Magnetic Sepharose Xtra
Beads, GE Healthcare) previously incubated with anti-GFP (3E6-2, mouse,
14 μg/ml). Immunoprecipitates were resolved by SDS-PAGE and gel bands
sent for mass spectrometry. Mass spectrometry data acquisition and analysis
(Program SpC PepShaker) was performed at the Mass Spectrometry and
Proteomics Laboratory (Department of Clinical Research, University of
Bern) essentially as described in Stettler et al. (2014).
Molecular modeling
Molecular modeling was performed on a Lenovo ThinkPad T440p (Lenovo)
using Schrödinger Suite Maestro (Maestro, version 10.2, Schrödinger, LLC,
2015) and Schrödinger Biologics Suite (BioLuminate, version 1.9,
Schrödinger, LLC, 2015). A human DDX3X model was generated based
on the high-resolution structure PDB 2I4I (resolution, 2.2 Å) using the protein
preparation wizard (standard settings; Schrödinger Suite 2015-2 Protein
Preparation Wizard; Epik version 3.2, Schrödinger, LLC, 2015; Impact
version 6.7, Schrödinger, LLC, 2015; Prime version 4.0, Schrödinger, LLC,
2015). Peptide models were generated using the build fragments tool and
molecular dynamics calculation (MacroModel, version 10.8, Schrödinger,
LLC, 2015). All systems were minimized using OPLS3 force field by default
settings implemented on the Schrödinger software package. Subsequently,
peptides were docked to human DDX3X and CK1δ/ε, respectively,
performing protein–protein docking.
Acknowledgements
We thank K. Aoki, C. Niehrs, T.J. Pugh, L. Kaufmann, C. Pichlo, and I. Neundorf for
reagents; M. Heller [mass spectrometry and Proteomics (PMSCF) University of
Bern] and S. Wiese [Core Unit mass spectrometry and Proteomics (CUMP), Ulm
University] for performing mass spectrometry analyses; M. Koloko for assistance in
ELISA and FTS experiments; E. Brunstein for technical assistance; O. Pertz and
R. Fritz for discussions and help with FRET sensors. We also thank the anonymous
reviewer for suggesting useful improvements to this manuscript.
Competing interests
The authors declare no competing or financial interests.
Author contributions
Conceptualization: C.D., J.B., S.G., U.B., B.S.; Methodology: C.D., J.B., S.G., U.B.,
U.K., B.S.; Validation: C.D., J.B., S.G., A.M.; Formal analysis: C.D., J.B., S.G., A.M.,
J.H., C.P., U.B., B.S.; Investigation: C.D., J.B., A.M., J.H., C.P.; Resources: J.B.,
H.K., B.S.; Data curation: C.D., S.G.; Writing - original draft: C.D., B.S.; Writing -
review & editing: C.D., J.B., S.G., B.S.; Visualization: C.D., J.B., S.G., J.H., C.P.;
Supervision: C.D., U.B., U.K., B.S.; Project administration: J.B., U.B., B.S.; Funding
acquisition: C.D., J.B., U.B., U.K., B.S.
Funding
C.D. acknowledges support by a Long-term Fellowship from the European
Molecular Biology Organization (EMBO) and by the Schweizerischer Nationalfonds
zur Förderung der Wissenschaftlichen Forschung (Swiss National Science
Foundation). J.B. acknowledges financial support by Ulm University
(Bausteinprogramm). This work was supported by the Canton of Bern and by a
Swiss National Science Foundation grant to B.S. Deposited in PMC for immediate
release.
Supplementary information
Supplementary information available online at
http://jcs.biologists.org/lookup/doi/10.1242/jcs.207316.supplemental
References
Bischof, J., Leban, J., Zaja, M., Grothey, A., Radunsky, B., Othersen, O., Strobl,
S., Vitt, D. andKnippschild, U. (2012). 2-Benzamido-N-(1H-benzo[d]imidazol-2-
yl)thiazole-4-carboxamide derivatives as potent inhibitors of CK1δ/ε.Amino Acids
43, 1577-1591.
Clevers, H. and Nusse, R. (2012). Wnt/β-catenin signaling and disease. Cell 149,
1192-1205.
Cordin, O., Banroques, J., Tanner, N. K. and Linder, P. (2006). The DEAD-box
protein family of RNA helicases. Gene 367, 17-37.
12
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs207316. doi:10.1242/jcs.207316
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
Cruciat, C.-M., Dolde, C., de Groot, R. E. A., Ohkawara, B., Reinhard, C.,
Korswagen, H. C. and Niehrs, C. (2013). RNA helicase DDX3 is a regulatory
subunit of casein kinase 1 in Wnt-β-catenin signaling. Science 339, 1436-1441.
Dolezal, T., Kucerova, K., Neuhold, J. and Bryant, P. J. (2010). Casein kinase I
epsilon somatic mutations found in breast cancer cause overgrowth in Drosophila.
Int. J. Dev. Biol. 54, 1419-1424.
Durocher, D. and Jackson, S. P. (2002). The FHA domain. FEBS Lett. 513, 58-66.
Epling, L. B., Grace, C. R., Lowe, B. R., Partridge, J. F. and Enemark, E. J.
(2015). Cancer-associated mutants of RNA helicase DDX3X are defective in
RNA-stimulated ATP hydrolysis. J. Mol. Biol. 427, 1779-1796.
Fritz, R. D., Letzelter, M., Reimann, A., Martin, K., Fusco, L., Ritsma, L.,
Ponsioen, B., Fluri, E., Schulte-Merker, S., van Rheenen, J. et al. (2013). A
versatile toolkit to produce sensitive FRET biosensors to visualize signaling in
time and space. Sci. Signal. 6, rs12-rs12.
Fuja, T. J., Lin, F., Osann, K. E. and Bryant, P. J. (2004). Somatic mutations and
altered expression of the candidate tumor suppressors CSNK1 epsilon, DLG1,
and EDD/hHYD in mammary ductal carcinoma. Cancer Res. 64, 942-951.
Gu, L., Fullam, A., Brennan, R. and Schröder, M. (2013). Human DEAD box
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